CABA MEXC RealStocks
Own real CABA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 17:06:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Cabaletta Bio, Inc. (CABA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.30, with a market capitalization of $286.91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.18 to $4.23. This page covers its latest market performance, valuation, price trends and company information.
$286.91M | |
$1.34 | |
$1.35 | |
$1.25 | |
$1.33 | |
1.39M | |
5.27M | |
-- | |
$4.23 | |
$1.18 | |
-- | |
-- |
Cabaletta Bio, Inc. (CABA) is currently trading at $1.30 as of 2026-11-13 17:05:00, down 3.38% ($0.05) from the previous close of $1.33
During today's regular trading session, CABA has traded between $1.26 and $1.35, with a trading volume of 1.39M shares. The current price is near the middle of today's range.
Over the past seven days, Cabaletta Bio, Inc. (CABA) moved from $1.28 to $1.30, representing a gain of 1.17% ($0.01).
The stock traded between $1.18 and $1.55 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 4.08 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.8%
CABA is currently trading at $1.30, placing it 3.8% of the way from its 52-week low of $1.18 to its 52-week high of $4.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 158 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cabaletta Bio, Inc. (CABA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CABA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CABA shares and USD.
CABA Shares to USD
1.00 CABA shares = 1.295 USD
Calculations are estimates based on the latest available price and are for reference only.